Jasper Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Jasper Therapeutics Stock-Based Compensation Growth & History (JSPR)
Jasper Therapeutics's stock-based compensation was $6.7M for fiscal 2025.
View full Jasper Therapeutics company overviewJasper Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.7M | $94,000 | +1.42% |
| 2024 | 2024-12-31 | $6.6M | $1.4M | +27.02% |
| 2023 | 2023-12-31 | $5.2M | $1.1M | +27.38% |
| 2022 | 2022-12-31 | $4.1M | $3.0M | +290.36% |
| 2021 | 2021-12-31 | $1.0M | −$162,000 | −13.39% |
| 2020 | 2020-12-31 | $1.2M | — | — |
Jasper Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $764,000 | −$1.1M | −57.95% |
| Q1 2026 | 2026-03-31 | $423,000 | −$1.4M | −76.64% |
| Q4 2025 | 2025-12-31 | $1.7M | −$309,000 | −15.69% |
| Q3 2025 | 2025-09-30 | $1.4M | −$574,000 | −28.73% |
| Q2 2025 | 2025-06-30 | $1.8M | $335,000 | +22.60% |
| Q1 2025 | 2025-03-31 | $1.8M | $642,000 | +54.92% |
| Q4 2024 | 2024-12-31 | $2.0M | $812,000 | +70.12% |
| Q3 2024 | 2024-09-30 | $2.0M | $603,000 | +43.23% |
| Q2 2024 | 2024-06-30 | $1.5M | $91,000 | +6.54% |
| Q1 2024 | 2024-03-31 | $1.2M | −$98,000 | −7.73% |
| Q4 2023 | 2023-12-31 | $1.2M | −$446,000 | −27.81% |
| Q3 2023 | 2023-09-30 | $1.4M | $751,000 | +116.61% |
| Q2 2023 | 2023-06-30 | $1.4M | $326,000 | +30.61% |
| Q1 2023 | 2023-03-31 | $1.3M | $489,000 | +62.85% |
| Q4 2022 | 2022-12-31 | $1.6M | $1.4M | +594.37% |
| Q3 2022 | 2022-09-30 | $644,000 | $449,000 | +230.26% |
| Q2 2022 | 2022-06-30 | $1.1M | $770,000 | +261.02% |
| Q1 2022 | 2022-03-31 | $778,000 | $451,000 | +137.92% |
| Q4 2021 | 2021-12-31 | $231,000 | — | — |
| Q3 2021 | 2021-09-30 | $195,000 | −$121,000 | −38.29% |
| Q2 2021 | 2021-06-30 | $295,000 | — | — |
| Q1 2021 | 2021-03-31 | $327,000 | — | — |
| Q3 2020 | 2020-09-30 | $316,000 | — | — |
Jasper Therapeutics stock-based compensation trends
Over the last five fiscal years, Jasper Therapeutics's stock-based compensation increased from $1.2M to $6.7M, a change of $5.5M. The latest reported quarter, Q2 2026, shows $764,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jasper Therapeutics source filings ↗